- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04722809
Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology (Botox)
Bruxism is defined as a parafunction that consists of a clenching of the jaw and/or grinding of the teeth. It can occur when an individual is sleeping or awake or it can be mixed.
Most often, it is primary or idiopathic bruxism, however when it is related to a cause it is qualified as secondary.
Primary bruxism is a condition that is not well known to the general public, but I is very widespread (12% of the adult population). In addition, it can alter quality of life, as a result of associated sleep disorders, concentration disorders, daytime fatigue, chronic pain, etc.
The current treatment for this condition is only symptomatic. Currently, one of the most effective treatments is the intramuscular injection of botulinum toxin A in the muscles of mastication. The progressive anticholinergic action results in a reduction of functional signs (dental pain, periodontal pain, temporomandibular joint pain, tension headaches, neck pain) and physical signs (reduction of the mass of the injected muscles, alba linea, tongue scalloping, limitation or stability of dental damage).
However, these clinical data are practically not objectified in daily practice. Objective criteria would make it possible to measure the effectiveness of the treatment, to follow the patient, and to identify the early symptoms in order to prevent a recurrence.
The aim of the prospective study is to concretely measure the strength and electromyographic activity of the muscles of mastication before and after botulinum toxin injection.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Narcisse ZWETYENGA
- Phone Number: 03 80 29 37 57
- Email: narcisse.zwetyenga@chu-dijon.fr
Study Locations
-
-
-
Dijon, France, 21000
- Recruiting
- CHU Dijon Bourgogne
-
Contact:
- Narcisse ZWETYENGA
- Phone Number: 03 80 29 37 57
- Email: narcisse.zwetyenga@chu-dijon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient who has given written consent.
- Patient between 18 and 64 years of age.
- Patient who has never received botulinum toxins
- Symptomatic patient in the context of bruxism in failure to the usual treatments (analgesic, physiotherapy, relaxation technique and maxillary retainer)
- Woman of childbearing age using an effective method of contraception
- Symptomatic patients in the context of bruxism, without a maxillary disocclusion retainer.
Exclusion Criteria:
- Protected Adult
- Patient not affiliated to the national health insurance system
- Pregnant or breastfeeding woman
- Refusal to take part in the study
- Neuromuscular diseases, including Myasthenia gravis, Myopathies, Amyotrophic Lateral Sclerosis. Lambert-Eaton Syndrome, patients with peripheral motor neuropathies, patients with underlying neurological disorders.
- Patients with a history of cardiovascular disease
- Patients with epilepsy or a previous seizure episode
- Neurogenic impairment of the face (including facial paralysis, polyradiculoneuritis)
- History of dysphagia or pulmonary aspiration
- Injection site infection (masseter and temporal)
- Hypersensitivity or allergy to botulinum toxin or any of its excipients.
- Treatment with aminoglycosides or anticholinesterase agents.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Symptomatic patients in the context of bruxism
|
Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side. At inclusion and 1 month post-injection.
Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®).
Measurements performed during normal sleeping conditions at home before injection and 1 month after.
Evaluation of jaw pain.
At inclusion and 3 months post-injection
anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction). At inclusion |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of episodes of nocturnal bruxism
Time Frame: 1 month after treatment by botulinum toxin injection
|
measurement of the number of bruxism episodes via a portable electromyogram we expect a significant improvement in the number of nocturnal bruxism episodes (decrease in relation to time 0)
|
1 month after treatment by botulinum toxin injection
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZWETYENGA CRBFC 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bruxism
-
Karabuk UniversityRecruiting
-
Riyadh Colleges of Dentistry and PharmacyUnknownNocturnal BruxismSaudi Arabia
-
Damascus UniversityCompletedNocturnal BruxismSyrian Arab Republic
-
University of California, San FranciscoWithdrawn
-
University of Nove de JulhoUnknown
-
Universidade Federal do Rio de JaneiroUnknown
-
CES UniversityNot yet recruitingSleep Bruxism, Childhood
-
Aydin Adnan Menderes UniversityCompleted
-
Dominik EttlinMerz PharmaceuticalsNot yet recruiting
-
Federal University of PelotasUnknown
Clinical Trials on Botulinum toxin injection
-
Assistance Publique - Hôpitaux de ParisMerz Pharmaceuticals GmbHUnknownTraumatic Brain Injury | Hemiparesis After StrokeFrance
-
YangHuiUnknown
-
Marmara UniversityCompletedStroke | Spasticity as Sequela of Stroke | Upper Limb HypertoniaTurkey
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Hospices Civils de LyonCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Zeng ChanghaoRecruitingCricopharyngeal AchalasiaTaiwan
-
HugelCompletedOveractive BladderKorea, Republic of
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
HugelCompletedCervical DystoniaKorea, Republic of